

Isoflurane & Sevoflurane: Mechanics & Effects

Part 1 of this 2-part series on inhalant anesthesia offers a review of the pharmacologic effects and mechanisms of these agents. Part 2 will describe application and follow-up protocols.

Patrick Burns, BVSc, MANZCVS, DACVAA
University of Montreal

P Profile

Mode of Action¹⁻³

- The exact mechanism of inhalant anesthetic agents is still unknown.
- There is potentiation of the GABA_A and glycine receptors, as well as inhibition of the acetylcholine and glutamate receptors.
- Inhalant anesthetics bind to the amphiphilic cavities in the proteins of cell membranes, causing conformational changes to receptors and transmembrane proteins.
 - There is a lack of synaptic transmission; this neuronal transmission interruption causes anesthesia.

Major Pharmacodynamic Effects

Central Nervous System

- The principal effects of inhalant anesthetics result in a state of general anesthesia with hypnosis, unconsciousness, amnesia (in humans), muscle relaxation, and immobility.
- Immobility is caused principally at the level of the spinal cord.
- Isoflurane and sevoflurane have been demonstrated to be neuroprotective.³
- Sevoflurane can better preserve the autoregulation mechanisms for brain vasculature; it is preferred over isoflurane for patients with neurologic disease.⁴

Pharmacologic Profile

- Isoflurane and sevoflurane are pharmacodynamically similar.
- Sevoflurane may be preferable in patients with certain heart or brain conditions.
- Sevoflurane has a lower blood-gas coefficient, which translates to a clinically faster response time to changes in concentration.
- Major factors that influence anesthetic uptake are anesthetic delivery to the lungs, blood-gas solubility, cardiac output, alveolar-to-venous anesthetic partial pressure difference, and tissue type.

Cardiovascular System

- All inhalant anesthetic agents produce an agent- and dose-dependent reduction in myocardial contractility, systemic vascular resistance, and cardiac preload with subsequent reductions in mean arterial pressure (MAP) and cardiac output in a dose-dependent manner.
- The most prominent effect at clinically pertinent minimum alveolar concentration (MAC) values is vasodilation caused directly by effects on vascular smooth muscle and indirectly by a reduction in sympathetic tone.⁵
 - This is dose dependent and may result in hypotension.
- At higher levels of anesthesia, negative inotropic effects are produced by changes in calcium availability and subsequent interaction with the actin-myosin cross-bridging.

MORE ►

GABA_A = class A γ -aminobutyric acid, MAC = minimum alveolar concentration, MAP = mean arterial pressure

- Sevoflurane has less of an effect on the autoregulation of the micro-circulation of the brain and heart when compared with isoflurane.⁴

Respiratory System

- The dose-dependent depression of respiratory function is similar in both inhalant anesthetics.
- Sevoflurane causes less bronchospasm than isoflurane, making it ideal for chamber or mask induction (Figure 1).⁶

Renal System

- Sevoflurane can be degraded by soda lime to compound A, which is nephrotoxic.⁷
- To minimize the risk for forming compound A, the newer calcium hydroxide-based CO₂ absorbents may be used; however, they have a lower absorbent capacity and are more costly.⁷
 - Low-flow anesthesia (ie, a low oxygen flow rate of less than 500

mL/min) should be avoided.^{1,6}

Minimum Alveolar Concentration

- The MAC of an anesthetic agent necessary to prevent movement in response to a supramaximal noxious stimulus in 50% of patients exposed.^{8,9}
- It is used to help determine the percentage of anesthetic agent to use.
 - For most species, the MAC of isoflurane and sevoflurane is about 1.3% and 2.3%, respectively.⁶
- There is an inverse relationship between potency and MAC and between MAC and the blood-gas coefficient.
 - Factors that can cause an *increase* in MAC requirements: anxiety, hyperthermia, thyrotoxicosis, and central nervous system stimulants
 - Factors that can cause a *decrease* in MAC requirements: hypothyroidism, hypothermia, hypotension, sedatives, analgesics, and pregnancy

Biotransformation of Anesthetics

- 0.2% of isoflurane is metabolized.^{1,7}
- <3% of sevoflurane is metabolized.¹

Inspired & Alveolar Anesthetic Concentrations

- The fraction alveolar concentration (F_A) equilibration with the fraction inspired concentration (F_I) signifies a steady state between the breathing circuit and the patient.
- The end-tidal agent concentration (ET_A) is used as a surrogate measure of the anesthetic concentration of the brain, which is the true measure of anesthetic depth.

Effect of Changes to the Ventilation

- The principal driving force that influences the anesthetic concentration in the brain is the F_A.
- A stable F_A implies that a steady state has been achieved between the alveolar space and all other compartments of the body (eg, blood, brain, muscles, fat).
- A F_A:F_I approaching 1 indicates a steady state with the other tissue compartments.
- How quickly the F_A:F_I ratio achieves a steady state is dependent on the ventilation of the patient and the uptake of the anesthetic agent.
- Increasing the ventilation of the patient when using a more soluble anesthetic such as isoflurane has a greater effect on the rate of increase in the F_A:F_I when compared with sevoflurane.
 - The uptake (the proportion of isoflurane absorbed by the pulmonary blood flow) of isoflurane is greater.
 - With isoflurane, if ventilation is doubled, uptake can be doubled, assuming cardiac output remains the same.
- As sevoflurane is relatively insoluble it will quickly achieve an equilibrium between all the tissue compartments.



Mask induction of a potbellied pig. Sevoflurane is the inhalant anesthetic of choice when using an anesthetic chamber or mask. After anesthesia is stable, a change over to isoflurane to reduce the costs of anesthesia may be preferable.

F_A = fraction alveolar concentration, F_I = fraction inspired concentration, ET_A = end-tidal agent concentration, GABA_A = class A γ-aminobutyric acid, MAC = minimum alveolar concentration, MAP = mean arterial pressure

Changes to the alveolar ventilation have less of an effect on the $F_A:F_I$ ratio as compared to isoflurane.

Factors Influencing Anesthetic Uptake

Solubility

- The relative solubility of an anesthetic agent between two different phases at a steady state is described by the partition coefficient.
- The blood–gas partition coefficient λ describes the interaction between the blood and the alveolar gas.
 - Isoflurane ($\lambda = 1.4$) has a higher blood–gas partition coefficient than sevoflurane ($\lambda = 0.65$).
 - At a steady state (ie, when the partial pressure is the same in each phase), more isoflurane is contained in the blood than the alveolar gas by a factor of 1.4.
 - The uptake of isoflurane is thus greater than sevoflurane.
 - The time required for isoflurane to obtain a steady $F_A:F_I$ ratio will be longer, which translates to a longer induction time for isoflurane, assuming normal ventilation–perfusion equilibrium.

Cardiac Output

- The higher the cardiac output, the higher the rate of uptake.
 - This is a result of more blood being in contact with the alveolar space with each minute.
 - This effect lowers the $F_A:F_I$ ratio.
 - The corollary of this is the

increased blood flow to other tissue compartments other than the brain, which also slows the rate of accumulation of the anesthetic agent in the brain.

Alveolar-to-Venous Partial Pressure Anesthetic Gradient

- As blood flows through the various tissue compartments, the tissue absorbs the anesthetic agent as a function of relative solubility.
- The greater the tissue absorption, the lower the venous partial pressure of the anesthetic agent.
 - This results in a larger alveolar-to-venous gradient, which slows the rate of increase in the $F_A:F_I$ ratio.
 - The high solubility in the other tissue compartments, especially fat, slows the rate of recovery because of the release of the anesthetic agents from these tissues back into the blood.
 - The principal difference between isoflurane and sevoflurane is the blood–gas partition coefficient (Table).

Tissue Groups

- The vessel-rich group (ie, brain, heart, splanchnic organs) has a relatively low mass (10% of body mass) but receives a high percentage of the cardiac output (75%).^{1,2,4}
 - These organs will receive more anesthetic faster as compared to other organs where the blood flow

is lower and the tissue mass is greater.

- After approximately 2 minutes, sevoflurane attains its equilibrium between the brain and blood (assuming normal ventilation and cardiac output in mammals).
 - Isoflurane takes 4–8 minutes to equilibrate.

Percentage of Anesthetic Agent Used

- Increasing the percentage of the anesthetic agent at the start of anesthesia also increases the F_I of the anesthetic agent.
- Doubling the percentage of anesthetic used does not result in doubling the rate of increase in the $F_A:F_I$ ratio because of the anesthesia-induced respiratory depression.

Rebreathing Circuits

- The gas inspired by a patient when using a rebreathing circuit is a mixture of fresh and exhaled gas, which is recycled and mixed again with fresh gas flow.
 - Uptake of anesthetic into the bloodstream slows the increase in the $F_A:F_I$ ratio as it prolongs the time to equilibrate for F_A .
- By using a fresh gas flow greater than the respiratory minute ventilation, the inspired gas will always be the same as the output of the vaporizer; however, this is wasteful and environmentally deleterious.

MORE ►

Table

Partition Coefficients of Isoflurane & Sevoflurane at 37°C⁷

Anesthetic	Blood–Gas	Brain–Blood	Liver–Blood	Kidney–Blood	Muscle–Blood	Fat–Blood
Sevoflurane	0.6	1.7	1.8	1.2	3.1	48
Isoflurane	1.4	1.6	1.8	1.2	2.9	45

- Higher flow rates also dry out the airways, so lower fresh gas flows are used.
- Two confounding problems slow the rate of increase of the anesthetic concentration in the circuit.
 - The lower fresh gas flow slows the rate of change in anesthetic concentration within the circuit.
 - The binding of volatile anesthetics onto the surface of the tubing of the circuit, CO₂ absorber, and uptake of anesthetic by the patient slows the rate of increase of the circuit anesthetic concentration.

In General

- When comparing isoflurane and sevoflurane using their pharmacokinetic profiles, the major difference is the blood-gas solubility coefficient.

- Changes in anesthetic concentration are more rapid with sevoflurane, but the MAC is higher when compared with isoflurane.
- Currently, sevoflurane is more expensive to use, because a higher fresh gas flow is recommended to prevent the formation of compound A when using a rebreathing circuit.
- Sevoflurane is the agent of choice for chamber and mask inductions and when a faster recovery is required.
- Sevoflurane may also have advantages over isoflurane in anesthesia for patients with brain disease.
- In anesthesia of cold-blooded species, sevoflurane may be preferable to isoflurane because of the shorter recovery period (Figure 2). ■ **cb**

See **Aids & Resources**, back page, for references & suggested reading.



In anesthesia of cold-blooded species, sevoflurane may be preferable to isoflurane because of the shorter recovery period.

MAC = minimum alveolar concentration

EASOTIC®

Otic suspension

(hydrocortisone aceponate, miconazole nitrate, gentamicin sulfate) Anti-inflammatory, antifungal, and antibacterial

For Otic Use in Dogs Only

CAUTION

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

BRIEF SUMMARY: Please consult package insert for complete product information.

INDICATIONS

EASOTIC® suspension is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (*Malassezia pachydermatis*) and bacteria (*Staphylococcus pseudintermedius*).

CONTRAINDICATIONS

Do not use in dogs with known tympanic membrane perforation.

EASOTIC® suspension is contraindicated in dogs with known or suspected hypersensitivity to corticosteroids, imidazole antifungals, or aminoglycoside antibiotics.

WARNINGS

Human Warnings: Not for use in humans. Keep this and all drugs out of reach of children.

Humans with known or suspected hypersensitivity to hydrocortisone, aminoglycoside antibiotics, or azole antifungals should not handle this product.

Animal Warnings: As a class, aminoglycoside antibiotics are associated with ototoxicity, vestibular dysfunction and renal toxicity. The use of EASOTIC® suspension in a dog with a damaged tympanic membrane can result in damage to the structures of the ear associated with hearing and balance or in transmission of the infection to the middle or inner ear. Immediately discontinue use of EASOTIC® suspension if hearing loss or signs of vestibular dysfunction are observed during treatment (see **ADVERSE REACTIONS**).

PRECAUTIONS

Do not administer orally.

Concurrent administration of potentially ototoxic drugs should be avoided.

Use with caution in dogs with impaired hepatic or renal function (see **ANIMAL SAFETY**).

Long-term use of topical otic corticosteroids has been associated with adrenocortical suppression and iatrogenic hyperadrenocorticism in dogs (see **ANIMAL SAFETY**).

The safe use of EASOTIC® suspension in dogs used for breeding purposes, during pregnancy, or in lactating bitches, has not been evaluated.

ADVERSE REACTIONS

In a field study conducted in the United States, there were no adverse reactions reported in 145 dogs administered EASOTIC® suspension.

In foreign market experience, reports of hearing loss and application site erythema have been received. In most reported cases, the hearing loss and erythema were transient and resolved with discontinuation of EASOTIC® suspension.

To report suspected adverse drug events, or for technical assistance contact Virbac at 800-338-3659.

ANIMAL SAFETY

Aural administration of EASOTIC® suspension to 12 week old Beagle dogs at 1, 3, and 5 times the recommended dose (1mL/ear/day) for 15 days (three times the treatment length) was associated with alterations of the hypothalamic-pituitary-adrenal axis as evidenced by the ACTH stimulation results. Other findings considered to be related to treatment include the development of aural hyperemia; the presence of renal tubular crystals and possibly renal tubular basophilia and atrophy; elevated liver weights; the development of otitis externa and media; and elevations in alanine aminotransferase, alkaline phosphatase, total protein, albumin, and cholesterol levels.

STORAGE INFORMATION: Store at temperatures between 20°C-25°C (68°F-77°F), with excursions permitted between 15°C-30°C (59°F-86°F).

HOW SUPPLIED: EASOTIC® suspension is supplied in a polyethylene canister, with a soft applicator canula.

Distributed by:

Virbac AH, Inc., Fort Worth, TX 76137 USA

NADA 141-330, Approved by FDA.

© 2013 Virbac Corporation

All Rights Reserved. Rev 8/2011